definit
mbl
defici
use
healthi
control
subject
publish
literatur
search
use
pubm
databas
identifi
studi
mbl
level
measur
elisa
genotyp
promot
structur
haplotyp
determin
investig
identifi
process
invit
particip
collabor
studi
individu
patient
data
collat
healthi
subject
studi
tabl
three
healthi
control
popul
includ
subject
fulli
character
genotyp
mbl
level
describ
elsewher
data
studi
made
avail
analysi
mbl
level
group
accord
genotyp
compar
use
kruskalw
test
receiv
oper
characterist
analysi
perform
use
mbl
level
predictor
lowestproduc
genotyp
suggest
cutoff
valu
mbl
defici
found
maxim
sensit
specif
mbl
valu
predict
lowproduc
genotyp
comparison
frequenc
mbl
defici
base
mbl
level
genotyp
perform
use
test
statist
analys
perform
minitab
releas
minitab
stata
version
statacorp
influenc
mbl
defici
outcom
sever
bacteri
infect
publish
studi
associ
mbl
defici
bacteri
infect
sepsi
identifi
search
pubm
databas
investig
invit
share
individu
patient
data
studi
includ
patient
mbl
level
andor
genotyp
determin
specif
mbl
level
measur
patient
tabl
blood
sampl
mbl
assay
obtain
day
diagnosi
sepsi
within
h
diagnosi
mbl
level
determin
doublesandwich
elisa
studi
dutch
periton
seri
mannanbind
elisa
use
patient
studi
combin
data
classifi
mbl
defici
replet
use
mbl
serum
level
cutoff
deriv
preced
analysi
healthi
control
subject
data
specif
organ
caus
sepsi
present
patient
patient
bacteremia
data
presenc
absenc
comorbid
record
total
patient
includ
inform
presenc
chronic
obstruct
pulmonari
diseas
hepatopathi
cancer
diabet
hiv
infect
patient
addit
patient
comorbid
classifi
basi
mccabe
score
qualiti
genet
associ
report
studi
assess
basi
publish
criteria
data
patient
includ
studi
mbl
sepsi
made
avail
studi
categor
variabl
compar
use
test
student
test
mannwhitney
logrank
test
use
compar
normal
nonnorm
distribut
variabl
respect
metaanalysi
binari
logist
regress
use
multivari
analysi
determin
associ
mbl
defici
death
statist
analys
perform
minitab
releas
stata
version
although
statist
signific
differ
mbl
serum
level
among
genotyp
group
kruskalw
logrank
test
markedli
decreas
level
least
intragroup
variat
seen
patient
genotyp
xao
oo
figur
mbl
level
patient
yao
genotyp
clearli
intermedi
obvious
lowproduc
genotyp
highproduc
mbl
group
yaya
yaxa
xaxa
xao
oo
group
chosen
definit
repres
genotyp
receiv
oper
characterist
analysi
reveal
mbl
level
reliabl
predictor
genotyp
area
receiv
oper
characterist
curv
figur
mbl
serum
level
maxim
sensit
specif
predict
lowproduc
genotyp
cutoff
posit
predict
valu
neg
predict
valu
level
propos
use
indic
mbl
defici
particularli
screen
purpos
high
neg
predict
valu
use
mbl
cutoff
level
determin
preval
mbl
defici
control
popul
studi
compar
preval
indic
lowproduc
genotyp
tabl
cohort
healthi
control
subject
includ
studi
rate
mbl
defici
defin
mbl
level
significantli
higher
defici
defin
lowproduc
genotyp
xao
oo
among
studi
mbl
sever
bacteri
infect
incorpor
combin
analysi
median
genet
associ
studi
qualiti
score
casecontrol
studi
cohort
studi
score
assess
moderatetohigh
qualiti
median
qualiti
score
higher
found
systemat
review
studi
genet
associ
sepsi
common
defici
studi
use
review
absenc
power
calcul
hardyweinberg
equilibrium
analysi
power
calcul
present
studi
perform
assum
mortal
rate
frequenc
mbl
defici
mortal
rate
chosen
midway
report
mortal
pneumococc
bacteremia
sever
sepsi
major
cohort
consist
patient
group
condit
assum
rel
risk
death
among
mbldefici
patient
patient
would
requir
achiev
power
detect
differ
group
p
valu
abl
evalu
surviv
among
patient
mbl
level
determin
substanti
number
requir
power
observ
overal
death
among
patient
mortal
inform
inhospit
surviv
relat
episod
sever
infect
avail
associ
serum
mbl
level
defici
death
infect
patient
determin
test
crude
pool
data
increas
rate
mbl
defici
among
patient
sever
bacteri
infect
die
patient
die
mbl
defici
compar
surviv
patient
surviv
mbl
defici
ci
metaanalysi
adjust
vari
preval
serum
mbl
level
defici
death
individu
studi
show
similar
effect
ci
indic
statist
signific
ci
figur
funnel
plot
indic
report
bia
studi
mbl
infect
outcom
figur
funnel
plot
involv
studi
includ
reanalysi
frequenc
serum
mbl
level
defici
could
ascertain
studi
mbl
sepsi
individu
patient
data
made
avail
multivari
analysi
defin
risk
factor
perform
patient
studi
apach
ii
score
calcul
adjust
apach
ii
score
age
sex
serum
mbl
level
defici
associ
trend
toward
increas
likelihood
death
among
infect
patient
ci
tabl
largest
subset
patient
sever
bacteri
infect
subset
pneumococc
diseas
patient
analyz
separ
major
patient
patient
came
studi
concentr
exclus
pneumonia
infect
apach
ii
score
calcul
addit
although
fine
score
calcul
patient
pneumococc
diseas
diseas
sever
index
could
use
multivari
analysi
factor
influenc
death
calcul
insuffici
number
patient
die
incorpor
therefor
presenc
bacteremia
patient
comorbid
use
instead
assess
independ
risk
factor
death
multivari
analysi
adjust
comorbid
bacteremia
age
sex
reveal
patient
pneumococc
infect
mbl
defici
increas
risk
death
tabl
studi
larg
cohort
healthi
subject
individu
data
drawn
studi
mbl
level
promot
andor
structur
genotyp
character
size
cohort
made
possibl
gener
far
greater
certainti
previou
studi
mbl
level
expect
lowestproduc
genotyp
assess
mbl
level
found
genotyp
group
reveal
interquartil
rang
patient
xao
oo
genotyp
substanti
lower
level
coincid
median
patient
yao
genotyp
furthermor
lower
quartil
patient
yao
approxim
upper
quartil
patient
xao
genotyp
patient
genotyp
yaya
yaxa
xaxa
median
mbl
level
clearli
higher
cutoff
basi
find
propos
patient
xao
oo
genotyp
consid
clearli
mbl
defici
would
inappropri
use
oo
group
alon
determin
mbl
defici
substanti
overlap
patient
xao
genotyp
subsequ
receiv
oper
characterist
analysi
confirm
mbl
level
valid
indic
presenc
genotyp
import
appreci
larg
variat
mbl
serum
level
seen
genotyp
group
nonparametr
distribut
valu
rang
obviou
explan
observ
genotyp
alon
poor
indic
presenc
low
mbl
level
therefor
mbl
defici
although
studi
reveal
serum
mbl
level
valid
indic
presenc
lowproduc
genotyp
xao
oo
low
level
also
found
signific
number
person
altern
genotyp
account
discrep
frequenc
mbl
defici
mbl
level
genotyp
definit
explor
studi
associ
mbl
defici
sever
bacteri
infect
convincingli
demonstr
reanalysi
larg
group
patient
previou
studi
confirm
previou
observ
trend
approach
statist
signific
found
mbl
defici
death
patient
sever
bacteri
infect
use
apach
ii
score
adjust
diseas
sever
incorpor
patient
risk
factor
age
sex
multivari
analysi
extend
previou
find
univari
associ
mbl
defici
death
due
sepsi
conflict
report
associ
invas
pneumococc
diseas
mbl
defici
also
seem
resolv
combin
analysi
first
time
knowledg
mbl
defici
shown
increas
risk
death
among
patient
pneumococc
infect
although
apach
ii
fine
score
could
use
adjust
pneumococc
diseas
sever
major
impact
mortal
comorbid
could
incorpor
multivari
analysi
find
suggest
patient
pneumococc
sepsi
may
import
group
investig
potenti
benefit
mbl
therapi
mbl
bind
microbi
cell
surfac
sugar
arrang
dens
spatial
array
refer
pathogenassoci
molecular
pattern
mbl
bind
pneumococcu
may
abrog
presenc
polysaccharid
capsul
must
recogn
mbl
pathway
minor
contributor
complementmedi
defenc
pneumonia
compar
classic
pathway
mbl
howev
also
contribut
bacteri
kill
noncompl
mechan
opsonophagocytosi
pathogen
pneumonia
isol
sampl
fewer
patient
studi
pneumonia
specif
smaller
number
patient
aureu
infect
may
explain
absenc
appar
signific
associ
mbl
defici
death
patient
insuffici
statist
power
multivari
analysi
data
shown
mbl
appear
play
role
respons
aureu
infect
bind
organ
precipit
deposit
increas
neutrophil
phagocytosi
compel
evid
mbl
knockout
mous
model
reveal
reduc
surviv
mblnull
anim
mbl
defici
appear
predispos
meningococc
sepsi
anoth
sever
infect
caus
encapsul
organ
clinic
associ
also
support
investig
abil
mbl
bind
facilit
kill
neisseria
meningitidi
small
number
patient
n
meningitidi
infect
current
studi
patient
previou
larg
studi
mbl
level
promot
haplotyp
determin
import
limit
present
studi
heterogen
control
infect
popul
nonetheless
larg
sampl
collect
multipl
racial
geograph
sourc
provid
opportun
demonstr
robust
associ
mbl
predisposit
sever
infect
differ
serum
mbl
level
test
methodolog
may
interfer
comparison
result
basic
laboratori
methodolog
use
result
healthi
control
popul
collat
methodolog
use
doubl
antimbl
sandwich
antibodi
elisa
perform
final
differ
may
exist
natur
serum
standard
use
produc
standard
curv
deriv
result
natur
acutephas
mbl
respons
studi
part
number
sepsi
studi
includ
studi
reveal
variat
mbl
level
factor
fold
one
studi
show
proport
septic
patient
increas
decreas
stabl
mbl
level
mbl
behav
acutephas
reactant
studi
context
pneumococc
infect
context
surgic
injuri
mbl
level
shown
alter
substanti
mark
comparison
known
acutephas
reactant
crp
unlik
therefor
substanti
decreas
mbl
level
result
consumpt
sepsi
caus
associ
low
mbl
level
sepsi
poor
outcom
particularli
pertin
associ
demonstr
mbl
defici
death
patient
pneumococc
sepsi
although
chang
mbl
correl
type
organ
caus
sepsi
shown
mbl
consum
sepsi
due
gramneg
gramposit
organ
mbl
may
extract
plasma
produc
recombin
mean
clinic
use
defici
septic
patient
phase
studi
mbl
infus
perform
mbl
long
serum
halflif
limit
experi
use
cystic
fibrosi
chronic
infect
recombin
human
mbl
replac
therapi
studi
clinic
trial
involv
patient
receiv
allogen
stem
cell
transplant
liver
transplant
data
larg
patient
cohort
report
suggest
serum
level
reliabl
indic
mbl
defici
clear
data
low
mbl
level
reliabl
indic
defici
presenc
lowproduc
genotyp
ration
deriv
mbl
serum
level
cutoff
defici
could
use
guid
replac
therapi
mbl
death
context
sever
bacteri
infect
especi
due
pneumococcu
associ
mbl
defici
adjust
bacteremia
age
comorbid
sever
bacteri
pneumonia
could
import
futur
target
studi
mbl
therapi
mortal
associ
bacterem
pneumococc
infect
remain
larg
unchang
despit
year
advanc
support
care
treatment
innat
immunebas
therapi
may
provid
new
opportun
reduc
substanti
diseas
burden
